These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21109957)

  • 1. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases.
    Yoshida K; Noguchi M; Mine T; Komatsu N; Yutani S; Ueno T; Yanagimoto H; Kawano K; Itoh K; Yamada A
    Oncol Rep; 2011 Jan; 25(1):57-62. PubMed ID: 21109957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.
    Yamamoto K; Mine T; Katagiri K; Suzuki N; Kawaoka T; Ueno T; Matsueda S; Yamada A; Itoh K; Yamana H; Oka M
    Oncol Rep; 2005 May; 13(5):874-83. PubMed ID: 15809753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
    Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
    Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
    Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
    Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
    Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.
    Menon AG; Kuppen PJ; van der Burg SH; Offringa R; Bonnet MC; Harinck BI; Tollenaar RA; Redeker A; Putter H; Moingeon P; Morreau H; Melief CJ; van de Velde CJ
    Cancer Gene Ther; 2003 Jul; 10(7):509-17. PubMed ID: 12833131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
    Miyagi Y; Imai N; Sasatomi T; Yamada A; Mine T; Katagiri K; Nakagawa M; Muto A; Okouchi S; Isomoto H; Shirouzu K; Yamana H; Itoh K
    Clin Cancer Res; 2001 Dec; 7(12):3950-62. PubMed ID: 11751487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
    Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
    J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
    N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.
    Guthmann MD; Castro MA; Cinat G; Venier C; Koliren L; Bitton RJ; Vázquez AM; Fainboim L
    J Immunother; 2006; 29(2):215-23. PubMed ID: 16531822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer].
    Hattori T; Okuno K; Yoshida K; Kokubu T; Mine T; Yamada R; Itoh K; Shiozaki H
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1745-7. PubMed ID: 17212094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients.
    Naito M; Itoh K; Komatsu N; Yamashita Y; Shirakusa T; Yamada A; Moriya F; Ayatuka H; Mohamed ER; Matsuoka K; Noguchi M
    Prostate; 2008 Dec; 68(16):1753-62. PubMed ID: 18767041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately.
    Saenger R; Maechler G; Potreck M; Zepp F; Knuf M; Habermehl P; Schuerman L
    Vaccine; 2005 Jan; 23(9):1135-43. PubMed ID: 15629356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.